How to treat Parkinson’s disease in 2013
Author:
Open Access
- 1 February 2013
- journal article
- review article
- Published by Elsevier in Clinical Medicine
- Vol. 13 (1) , 93-96
Abstract
Parkinson's disease is a common, progressive, debilitating disease with substantial physical, psychological and social implications. Pharmacological management is complex and should be individualised according to the needs of the patient. In early disease, treatment is generally highly effective, but medication becomes increasingly inadequate in controlling motor fluctuations and dyskinesias as the disease progresses. Non-motor symptoms, especially depression and dementia, require a holistic, multidisciplinary approach to maximise quality of life for patients and their carers. For the future, the ideal solution remains neuroprotection and restoration. Progress has been hampered by the lack of animal models that reflect the widespread brain pathology presumed to cause both motor and non-motor symptoms of PD in humans. Currently, agents are undergoing clinical trials in early, mildly affected patients, such as the plant-derived substance PYM50028 (Cogane), which promotes expression of endogenous neural growth factors and has shown promise in vitro and in animal models. Gene-therapy trials in progress rely on the viral vectors used to deliver the enzymatic machinery required for dopamine synthesis to the striatum. As PD progresses, adequate control of motor symptoms depends increasingly on continuous drug delivery, and greater physiological stimulation of dopamine receptors may help to prevent the development of LIDs and motor fluctuations. Efforts thus are afoot to develop better delivery systems for levodopa, and a new sustained-release formulation is in development.Keywords
This publication has 18 references indexed in Scilit:
- The treatment of early Parkinson's disease: levodopa rehabilitatedPractical Neurology, 2011
- Impulse control disorders in parkinson disease: A multicenter case–control studyAnnals of Neurology, 2011
- Age of Parkinson's disease onset as a predictor for the development of dyskinesiaMovement Disorders, 2010
- The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK populationJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Optimizing Long-Term Therapy for Parkinson DiseaseClinical Neuropharmacology, 2008
- A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Suboptimal medication adherence in Parkinson's diseaseMovement Disorders, 2005
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- Practical approach to quality of life in Parkinson’s disease: the nurse’s roleJournal of Neurology, 1998
- The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1988